A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
Phase of Trial: Phase II
Latest Information Update: 09 Oct 2017
At a glance
- Drugs Carboplatin (Primary) ; Pembrolizumab (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 03 Oct 2017 Status changed from not yet recruiting to recruiting.
- 04 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Sep 2022.
- 04 Aug 2017 Planned primary completion date changed from 1 May 2017 to 1 Sep 2021.